Decreased serum osteoprotegerin levels in patients with cardiac syndrome X

Basit Öğe Kaydı
dc.authoridAltun, Armagan/0000-0002-3233-8263
dc.authorwosidAltun, Armagan/ABB-5844-2020
dc.contributor.authorAltun, A
dc.contributor.authorUgur-Altun, B
dc.contributor.authorTatli, E
dc.date.accessioned2024-06-12T10:55:44Z
dc.date.available2024-06-12T10:55:44Z
dc.date.issued2004
dc.departmentTrakya Üniversitesien_US
dc.description13th European Congress on Obesity -- MAY 26-29, 2004 -- Prague, CZECH REPUBLICen_US
dc.description.abstractReceptor activator of nuclear factor kappaB (RANK) and osteoprotegerin (Cl represent the ligand and decoy receptor, respectively, of a pleiotropic cytokine system that regulates bone metabolism and vascular biology. Several studies supported systemic microvascular abnormalities in patients with cardiac syndrome X (CSX). This study investigates serum Cl levels in healthy obese subjects and healthy lean controls affected by cardiac syndrome X. Methods: We compared the Cl levels in 8 patients with cardiac syndrome X [2 males, 6 females; age: 46 +/- 6 yr; body mass index (BMI): 30 +/- 5 kg/m(2)] with 24 obese subjects (8 males, 16 females; age: 38 +/- 5 yr; BMI: 35 +/- 5 kg/m(2)) and 15 healthy lean controls (6 males, 9 females; age: 36 +/- 5 yr; BMI: 23 +/- 2 kg/m(2); BMI<25kg/m(2)). Results: Serum Cl levels in patients with cardiac syndrome X were lower than those in obese subjects and lean controls (11..45 +/- 8.36 pg/ml, 14.78 +/- 8.22 pg/mI, 19.24 +/- 6.96 pg/ml, respectively, cardiac syndrome X vs lean controls, P = 0.039). Conclusions: Serum OPG levels are lower in patients with CSX. Further studies on the mechanisms of OPG in microangiopathy may help to evaluate the OPG system role as a marker for disease activity, prognosis and response to therapy in cardiovascular diseases. (C) 2004, Editrice Kurtis.en_US
dc.identifier.doi10.1007/BF03346278
dc.identifier.endpage843en_US
dc.identifier.issn0391-4097
dc.identifier.issn1720-8386
dc.identifier.issue9en_US
dc.identifier.pmid15648548en_US
dc.identifier.scopus2-s2.0-14544289680en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage839en_US
dc.identifier.urihttps://doi.org/10.1007/BF03346278
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19534
dc.identifier.volume27en_US
dc.identifier.wosWOS:000225954100008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal Of Endocrinological Investigationen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCardiac Syndrome Xen_US
dc.subjectOsteoprotegerinen_US
dc.subjectMicroangiopathyen_US
dc.subjectObesityen_US
dc.subjectNf-Kappa-Ben_US
dc.subjectCoronary Flow Velocityen_US
dc.subjectMicrovascular Anginaen_US
dc.subjectRank Liganden_US
dc.subjectIncreaseen_US
dc.subjectReceptoren_US
dc.subjectPainen_US
dc.titleDecreased serum osteoprotegerin levels in patients with cardiac syndrome Xen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu